Mohummad Minhaj Siddiqui, MD Joins Greenebaum Cancer Center
For immediate release: July 30, 2014
Urologic surgeon is lead author on recent study connecting vasectomy to increased risk for advanced prostate cancer
Mohummad Minhaj Siddiqui, MD, a urologic surgeon with a strong focus on prostate and bladder cancer, recently joined the faculty at the University of Maryland School of Medicine as assistant professor of surgery and is an associate member of the Hormone Responsive Cancers Program at the University of Maryland Marlene and Stewart Greenebaum Cancer Center.
Dr. Siddiqui received his medical degree from Harvard Medical School and completed residencies in general surgery and urology at Massachusetts General Hospital. A fellowship in urologic oncology at the National Cancer Institute followed, where Dr. Siddiqui focused on advanced MRI imaging of prostate tumors. In addition to providing patient care at the University of Maryland Medical Center, Dr. Siddiqui will continue to actively pursue prostate cancer research for advancing methods for diagnosis and treatment of the disease.
Dr. Siddiqui was the lead author of a recently published study that found that men who have had vasectomies have a higher risk of developing advanced or lethal prostate cancer. The study was conducted at Harvard Medical School and was published online July 7 in the Journal of Clinical Oncology. It is the largest and most comprehensive study to look at the link between vasectomy and prostate cancer to date.
Dr. Siddiqui is particularly interested in finding better ways to differentiate aggressive prostate cancer from non-aggressive cancer using cell metabolism and MRI imaging. Only a fraction of men diagnosed with prostate cancer have the aggressive form of the disease and require treatment. Those with non-aggressive disease who receive standard treatment – full-prostate radiation or removal of the prostate – often suffer side effects that drastically impact quality of life such as incontinence and/or impotence. Dr. Siddiqui's research is aimed at differentiating between aggressive and non-aggressive disease so as to allow doctors to treat those who require it, while sparing men who don't require treatment the life–changing side effects. To accomplish this goal, he will utilize new technology, called MRI/Ultrasound fusion, to guide biopsies. This technique will allow him to more reliably diagnose high risk disease using fewer biopsies. When high risk disease is detected through biopsy, he will use focal prostate cancer therapy–targeting just the tumor–to try to avoid the side effects that can occur with whole gland treatment.